Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.

Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F, Fernando L, Dietze R, Luz K, Venâncio da Cunha R, Jimeno J, López-Medina E, Borkowski A, Brose M, Rauscher M, LeFevre I, Bizjajeva S, Bravo L, Wallace D; TIDES Study Group.

N Engl J Med. 2019 Nov 21;381(21):2009-2019. doi: 10.1056/NEJMoa1903869. Epub 2019 Nov 6.

PMID:
31693803
2.

[Risk factors and lethality associated with neonatal candidemia in a neonatal unit].

Caparó Ingram E, Vásquez Vega M, Norero X, Sáez-Llorens X, DeAntonio R, Rodríguez Barría E.

Rev Chil Pediatr. 2019 Apr;90(2):186-193. doi: 10.32641/rchped.v90i2.717. Spanish.

3.

Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.

Gaensbauer JT, Gast C, Bandyopadhyay AS, O'Ryan M, Saez-Llorens X, Rivera L, Lopez-Medina E, Melgar M, Weldon WC, Oberste MS, Rüttimann R, Clemens R, Asturias EJ.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S57-S65. doi: 10.1093/cid/ciy649.

4.

Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.

Sáez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM, Mensi I, Keshavan P, Toneatto D.

Hum Vaccin Immunother. 2018 May 4;14(5):1161-1174. doi: 10.1080/21645515.2018.1457595. Epub 2018 May 9.

5.

Ethical Considerations for the Participation of Children of Minor Parents in Clinical Trials.

Ott MA, Crawley FP, Sáez-Llorens X, Owusu-Agyei S, Neubauer D, Dubin G, Poplazarova T, Begg N, Rosenthal SL.

Paediatr Drugs. 2018 Jun;20(3):215-222. doi: 10.1007/s40272-017-0280-y.

6.

Factors influencing access of pregnant women and their infants to their local healthcare system: a prospective, multi-centre, observational study.

Madhi SA, Rivera LM, Sáez-Llorens X, Menéndez C, Carrim-Ganey N, Cotton MF, Katzman D, Luttig MM, Candelario R, Baker S, Roychoudhury M.

BMC Pregnancy Childbirth. 2018 Jan 15;18(1):29. doi: 10.1186/s12884-017-1655-3.

7.

Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.

Brickley EB, Strauch CB, Wieland-Alter WF, Connor RI, Lin S, Weiner JA, Ackerman ME, Arita M, Oberste MS, Weldon WC, Sáez-Llorens X, Bandyopadhyay AS, Wright PF.

J Infect Dis. 2018 Jan 17;217(3):371-380. doi: 10.1093/infdis/jix556.

8.

Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study.

Sáez-Llorens X, Tricou V, Yu D, Rivera L, Jimeno J, Villarreal AC, Dato E, Mazara S, Vargas M, Brose M, Rauscher M, Tuboi S, Borkowski A, Wallace D.

Lancet Infect Dis. 2018 Feb;18(2):162-170. doi: 10.1016/S1473-3099(17)30632-1. Epub 2017 Nov 6.

PMID:
29122463
9.

Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.

Sáez-Llorens X, Rowley S, Wong D, Rodríguez M, Calvo A, Troitiño M, Salas A, Vega V, Castrejón MM, Lommel P, Pascal TG, Hausdorff WP, Borys D, Ruiz-Guiñazú J, Ortega-Barría E, Yarzabal JP, Schuerman L.

Hum Vaccin Immunother. 2017 Jun 3;13(6):1-16. doi: 10.1080/21645515.2017.1287640. Epub 2017 Feb 25.

10.

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.

Sáez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, Borkowski A, Wallace D.

Lancet Infect Dis. 2017 Jun;17(6):615-625. doi: 10.1016/S1473-3099(17)30166-4. Epub 2017 Mar 30.

PMID:
28365225
11.

Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.

Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, Melgar M, Gaensbauer JT, Weldon WC, Oberste MS, Borate BR, Gast C, Clemens R, Orenstein W, O'Ryan G M, Jimeno J, Clemens SA, Ward J, Rüttimann R; Latin American IPV001BMG Study Group.

Lancet. 2016 Jul 9;388(10040):158-69. doi: 10.1016/S0140-6736(16)00703-0. Epub 2016 May 19. Erratum in: Lancet. 2016 Jul 9;388(10040):e2.

PMID:
27212429
12.

Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.

Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS.

Lancet Infect Dis. 2016 Mar;16(3):321-30. doi: 10.1016/S1473-3099(15)00488-0. Epub 2015 Dec 21.

PMID:
26719058
13.

Incidence and serotype distribution of invasive group B streptococcal disease in young infants: a multi-country observational study.

Rivera L, Sáez-Llorens X, Feris-Iglesias J, Ip M, Saha S, Adrian PV, Madhi SA, Boudville IC, Cunnington MC, Casellas JM, Slobod KS.

BMC Pediatr. 2015 Oct 1;15:143. doi: 10.1186/s12887-015-0460-2.

14.

Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922.

Pavia-Ruz N, Rossouw M, Sáez-Llorens X, Bunupuradah T, Taylor M, Yang R, Sevinsky H, Krystal M, Lataillade M, Seekins D, Biguenet S.

Pediatr Infect Dis J. 2015 Dec;34(12):1355-60. doi: 10.1097/INF.0000000000000913.

PMID:
26379163
15.

Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents.

Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Han L, Smolenov I, Dull P.

Pediatr Infect Dis J. 2015 Oct;34(10):e264-78. doi: 10.1097/INF.0000000000000822.

PMID:
26135245
16.

Correction: Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial.

Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Rodriguez M, Troitiño M, Carabajal C, Falaschi A, Leandro A, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L; COMPAS Group.

PLoS Med. 2015 Jun 26;12(6):e1001850. doi: 10.1371/journal.pmed.1001850. eCollection 2015 Jun. No abstract available.

17.

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.

Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Graña MG, Heijnen E, Smolenov I, Dull PM.

Hum Vaccin Immunother. 2015;11(6):1507-17. doi: 10.1080/21645515.2015.1029686.

18.

A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.

Saez-Llorens X, Castaño E, Rathore M, Church J, Deville J, Gaur A, Estripeaut D, White K, Arterburn S, Enejosa JV, Cheng AK, Chuck SL, Rhee MS.

Pediatr Infect Dis J. 2015 Apr;34(4):376-82. doi: 10.1097/INF.0000000000000289.

PMID:
25760565
19.

Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.

Tregnaghi MW, Sáez-Llorens X, López P, Abate H, Smith E, Pósleman A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, Tregnaghi M, Sierra A, Rodriguez M, Troitiño M, Carabajal C, Falaschi A, Leandro A, Castrejón MM, Lepetic A, Lommel P, Hausdorff WP, Borys D, Ruiz Guiñazú J, Ortega-Barría E, Yarzábal JP, Schuerman L; COMPAS Group.

PLoS Med. 2014 Jun 3;11(6):e1001657. doi: 10.1371/journal.pmed.1001657. eCollection 2014 Jun. Erratum in: PLoS Med. 2015 Jun;12(6):e1001850.

20.

A consensus statement: meningococcal disease among infants, children and adolescents in Latin America.

Rüttimann RW, Gentile A, Parra MM, Saez-Llorens X, Safadi MA, Santolaya ME.

Pediatr Infect Dis J. 2014 Mar;33(3):284-90. doi: 10.1097/INF.0000000000000228. Erratum in: Pediatr Infect Dis J. 2014 May;33(5):548.

PMID:
24463807
21.

Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.

Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP; Motavizumab Study Group.

Pediatr Infect Dis J. 2014 Jul;33(7):703-9. doi: 10.1097/INF.0000000000000240.

PMID:
24356256
22.

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative.

Sáfadi MA, de los Monteros LE, López EL, Sàez-Llorens X, Lemos AP, Moreno-Espinosa S, Ayala SG, Torres JP, de Moraes JC, Vázquez JA.

Expert Rev Vaccines. 2013 Aug;12(8):903-15. doi: 10.1586/14760584.2013.814879. Epub 2013 Aug 5. Review.

PMID:
23909747
23.

A multi-country study of intussusception in children under 2 years of age in Latin America: analysis of prospective surveillance data.

Sáez-Llorens X, Velázquez FR, Lopez P, Espinoza F, Linhares AC, Abate H, Nuñez E, Venegas G, Vergara R, Jimenez AL, Rivera M, Aranza C, Richardson V, Macias-Parra M, Palacios GR, Rivera L, Ortega-Barria E, Cervantes Y, Rüttimann R, Rubio P, Acosta CJ, Newbern C, Verstraeten T, Breuer T.

BMC Gastroenterol. 2013 May 27;13:95. doi: 10.1186/1471-230X-13-95.

24.

Brain abscess.

Sáez-Llorens X, Nieto-Guevara J.

Handb Clin Neurol. 2013;112:1127-34. doi: 10.1016/B978-0-444-52910-7.00032-5. Review.

PMID:
23622320
25.

[Methicillin-resistant Staphylococcus aureus disease in Panama].

Luciani K, Nieto-Guevara J, Sáez-Llorens X, de Summan O, Morales D, Cisternas O, Bolaños R, Ramos R, Estripeaut D.

An Pediatr (Barc). 2011 Aug;75(2):103-9. doi: 10.1016/j.anpedi.2011.02.008. Epub 2011 Mar 31. Spanish.

26.

Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America.

Tregnaghi MW, Abate HJ, Valencia A, Lopez P, Da Silveira TR, Rivera L, Rivera Medina DM, Saez-Llorens X, Gonzalez Ayala SE, De León T, Van Doorn LJ, Pilar Rubio MD, Suryakiran PV, Casellas JM, Ortega-Barria E, Smolenov IV, Han HH; Rota-024 Study Group.

Pediatr Infect Dis J. 2011 Jun;30(6):e103-8. doi: 10.1097/INF.0b013e3182138278.

PMID:
21378594
27.

Impact of routine fluconazole prophylaxis for premature infants with birth weights of less than 1250 grams in a developing country.

Rueda K, Moreno MT, Espinosa M, Sáez-Llorens X.

Pediatr Infect Dis J. 2010 Nov;29(11):1050-2. doi: 10.1097/INF.0b013e3181e9dea2.

PMID:
20571460
28.

[Impact of vaccination against rotavirus on hospitalization for acute severe gastroenteritis].

Sáez-Llorens X.

Rev Panam Salud Publica. 2009 Apr;25(4):375-6; author reply 376. Spanish. No abstract available.

PMID:
19531327
29.

Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.

Sáez-Llorens X, Yogev R, Arguedas A, Rodriguez A, Spigarelli MG, De León Castrejón T, Bomgaars L, Roberts M, Abrams B, Zhou W, Looby M, Kaiser G, Hamed K.

Antimicrob Agents Chemother. 2009 May;53(5):1912-20. doi: 10.1128/AAC.01054-08. Epub 2009 Mar 9.

30.

Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.

Sáez-Llorens X, Macias M, Maiya P, Pineros J, Jafri HS, Chatterjee A, Ruiz G, Raghavan J, Bradshaw SK, Kartsonis NA, Sun P, Strohmaier KM, Fallon M, Bi S, Stone JA, Chow JW.

Antimicrob Agents Chemother. 2009 Mar;53(3):869-75. doi: 10.1128/AAC.00868-08. Epub 2008 Dec 15.

31.

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study.

Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X, Abate H, Espinoza F, López P, Macías-Parra M, Ortega-Barría E, Rivera-Medina DM, Rivera L, Pavía-Ruz N, Nuñez E, Damaso S, Ruiz-Palacios GM, De Vos B, O'Ryan M, Gillard P, Bouckenooghe A; Human Rotavirus Vaccine Study Group.

Lancet. 2008 Apr 5;371(9619):1181-9. doi: 10.1016/S0140-6736(08)60524-3.

PMID:
18395579
32.

[Economic impact of rotavirus vaccination in Panama].

Constenla D, Ortega-Barría E, Rheingans RD, Antil L, Sáez-Llorens X.

An Pediatr (Barc). 2008 Feb;68(2):128-35. Spanish.

33.

Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.

Saez-Llorens X, Violari A, Ndiweni D, Yogev R, Cashat M, Wiznia A, Chittick G, Harris J, Hinkle J, Blum MR, Adda N, Rousseau F; FTC-203 Study Team.

Pediatrics. 2008 Apr;121(4):e827-35. doi: 10.1542/peds.2006-3078. Epub 2008 Mar 10.

PMID:
18332076
34.

Rocky Mountain spotted fever, Panama.

Estripeaut D, Aramburú MG, Sáez-Llorens X, Thompson HA, Dasch GA, Paddock CD, Zaki S, Eremeeva ME.

Emerg Infect Dis. 2007 Nov;13(11):1763-5. doi: 10.3201/eid1311.070931.

35.

Glycerol and bacterial meningitis.

Sáez-Llorens X, McCracken GH Jr.

Clin Infect Dis. 2007 Nov 15;45(10):1287-9. Epub 2007 Oct 15. No abstract available.

PMID:
17968822
36.

Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.

Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ.

Pediatr Infect Dis J. 2007 Oct;26(10):868-78.

PMID:
17901791
37.

Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development.

Rubino CM, Ambrose P, Cirincione B, Arguedas A, Sher L, Lopez E, Sáez-Llorens X, Grasela DM.

Diagn Microbiol Infect Dis. 2007 Sep;59(1):67-74.

PMID:
17875453
38.

[Seroprevalence of cytomegalovirus infection in puerperal women and its impact on their newborns].

Estripeaut D, Moreno Y, Ahumada Ruiz S, Martínez A, Racine JD, Sáez-Llorens X.

An Pediatr (Barc). 2007 Feb;66(2):135-9. Spanish.

39.

[Dengue infection in children and adolescents in Panama].

Larrú Martínez B, Quiroz E, Bellón JM, Esquivel R, Nieto Guevara J, Sáez-Llorens X.

An Pediatr (Barc). 2006 Jun;64(6):517-22. Spanish.

40.

[Persistence of dengue in the tropics].

Sáez-Llorens X.

An Pediatr (Barc). 2006 Jun;64(6):515-6. Spanish. No abstract available.

41.

Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis.

Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M; Human Rotavirus Vaccine Study Group.

N Engl J Med. 2006 Jan 5;354(1):11-22.

42.

Gatifloxacin therapy for children: turn on the light.

Echols R, Hamed K, Arguedas A, Dagan R, Sher L, Sáez-Llorens X, Pichichero ME.

Clin Infect Dis. 2005 Dec 15;41(12):1824-5. No abstract available.

PMID:
16288415
43.

[Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children].

Sáez-Llorens X, Castrejón de Wong MC, Castaño E, de Suman O, Báez de Ulloa C, Redondo W, Espino M.

Rev Med Panama. 2001;26:13-8. Spanish.

PMID:
16161718
44.

Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure.

Pichichero ME, Arguedas A, Dagan R, Sher L, Saez-Llorens X, Hamed K, Echols R.

Clin Infect Dis. 2005 Aug 15;41(4):470-8. Epub 2005 Jul 13. Review.

PMID:
16028153
45.

Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children.

Sáez-Llorens X, Rodriguez A, Arguedas A, Hamed KA, Yang J, Pierce P, Echols R.

Pediatr Infect Dis J. 2005 Apr;24(4):293-300.

PMID:
15818287
46.

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH Jr, Connor EM; MEDI-493 Study Group.

Pediatr Infect Dis J. 2004 Aug;23(8):707-12.

PMID:
15295219
47.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N.

Antimicrob Agents Chemother. 2004 Jun;48(6):2166-72.

48.

Intussusception and rotavirus vaccines: what is the background risk?

Sáez-Llorens X, Guevara JN.

Pediatr Infect Dis J. 2004 Apr;23(4):363-5.

PMID:
15071297
49.

Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children.

McCoig C, Castrejón MM, Saavedra-Lozano J, Castaño E, Báez C, Lanier ER, Sáez-Llorens X, Ramilo O.

Pediatr Infect Dis J. 2004 Feb;23(2):114-8.

PMID:
14872175
50.

Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure.

Arguedas A, Sher L, Lopez E, Sáez-Llorens X, Hamed K, Skuba K, Pierce PF.

Pediatr Infect Dis J. 2003 Nov;22(11):949-56.

PMID:
14614365

Supplemental Content

Loading ...
Support Center